Phase 1 N=45 Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Hypertrophic Cardiomyopathy
Primary: Area Under the Curve (AUC) (0-last), AUC(0-inf) — 9956; 20040; 18270; 39980 h*ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=53 A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
Schizophrenia
Primary: Number of Participants Experiencing an Adverse Event (AE) — 3; 2; 0; 3 Participants
Phase 1 N=45 A Safety Study of Mirikizumab (LY3074828)
Psoriasis
Primary: Number of Participants With One or More Adverse Event(s) (AEs) Considered by the Investigator to Be Related to Study Drug Administration — 1; 1; 2; 0 Participants
Phase 1 N=72 A Study of LY3478045 in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 1 N=21 Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
Glioblastoma
Primary: Increase of Interferon Gamma Levels — 0 Participants
Phase 1 N=48 Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
Multi-drug Resistant Tuberculosis
Primary: Relative Bioavailability - Cmax — 2170; 1180; 1850; 1090 ng/mL — p=0.0001
Phase 1 N=34 Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
Dermatitis, Atopic
Primary: Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1 — -66.11; -32.81 Percent Change
Phase 1 N=47 A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)
Gram-Positive Infections
Primary: Part A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After…
Phase 1 N=315 Live Enterovirus Vaccine and Type 1 Diabetes
Enterovirus Infection · Type 1 Diabetes · Prediabetic State
Primary: Number of Participants With the Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum — 17; 2 Participants
Phase 1 N=87 A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Advanced Solid Tumor · Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events (≥10% Overall) in Participants Receiving Milademetan — 3; 1; 1; 33 Participants
Phase 1 N=36 M6620 Plus Standard Treatment in Oesophageal and Other Cancer
Oesophageal Adenocarcinoma · Squamous Cell Carcinoma · Solid Tumor
Primary: STAGE A1 - Number of Dose Limiting Toxicities for M6620 (Berzosertib) Administered Concomitantly With Radiotherapy (RT) in the Palliative Treatment of Oesophageal…
Phase 1 N=8 A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
Smoking Cessation
Primary: Number of Adverse Events — 5; 0; 1; 1 Participants
Phase 1 N=58 Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
AIDS-Related Non-Hodgkin Lymphoma · Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8
Primary: Frequency of Observed Adverse Events (AEs) — 100; 100; 100; 100 percentage of participants
Phase 1 N=22 Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers
Healthy Volunteers
Primary: Percentage of Dose Excreted in Urine - MB Cohort — 3.81 Percentage
Phase 1 N=42 Inhibition of Sterile Inflammation by Digoxin
Inflammatory Response
Primary: Lower Levels of Spontaneous Reactive Oxygen Species (ROS) Production